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Abstract: The measurement of patient-reported outcome measures (PROMs) following head 
and neck cancer (HNC) has the capacity to substantially enhance the care of patients and their 
care-givers following the diagnosis and treatment of HNC. Literature concerning PROMs 
has increased exponentially in the past 2 decades, producing a vast array of data upon which 
the multidisciplinary team can reflect. For this review, “Handle On QOL” has been used as a 
source of references to illustrate the points raised. PROMs are contextualized by considering 
the clinically-distinct key stages that cancer patients endure: diagnosis, treatment, acute toxicity, 
early recovery, late effects, recurrence, and palliation. The PROMs are considered in six main 
categories: 1) those addressing cornucopia of issues not specific to cancer; 2) those addressing 
issues common to all cancers; 3) questionnaires with items specific to HNC; 4) questionnaires 
that focus on a particular aspect of head and neck function; 5) those measuring psychological 
concerns, such as depression, anxiety, or self-esteem; and 6) item prompt lists. Potential benefits 
of PROMs in clinical practice are discussed, as are barriers to use. The way forward in integrat-
ing PROMs into routine HNC care is discussed with an emphasis on information technology. 
Keywords: patient reported outcomes, head and neck cancer, quality of life, multi-professional
What is head and neck cancer (HNC)?
HNCs are neoplasms of the upper aerodigestive tract and ascribed the International 
Classification of Diseases codes 140-149 and 160-1.1 This includes tumor sites involv-
ing the oral cavity, oropharynx, larynx, hypopharynx, paranasal sinuses, and salivary 
glands. HNC surgeons and oncologists, through multi-professional collaboration, are 
also involved in the treatment of thyroid and skull base lesions, as well as extensive 
facial neoplasms. Over 90% of HNCs are squamous cell carcinomas (SCC), though 
other non-epithelial pathologies are present, such as lymphoma, melanoma, sarcoma, 
and odontogenic tumors.2,3
In North America and Europe, HNCs account for ~5%–10% of cancers; however, 
there is significant geographical variation spanning incidence and anatomic site world-
wide. For example, in high-risk countries such as India, Sri Lanka, or Bangladesh, oral 
cavity SCC is the most common cancer in men and the third most common cancer 
in women.4 Yet, in the United States, head and neck SCC is the eighth most common 
cancer in men with ~53,600 patients diagnosed annually.5 This can be attributed to 
differences in exposure to causative carcinogenic agents globally, which contributes to 
development of nearly 80% of all HNSCC diagnosed worldwide.6 Causative etiologies 
include traditional carcinogens such as smoking, alcohol, and betel nuts. However, 
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more recently, the human papillomavirus (HPV) has been 
responsible for an epidemic-like increase in the incidence 
of oropharyngeal SCC worldwide.7,8
What treatments are involved?
The treatment of HNC varies by site and stage of disease.9 
In early cancers, single modality treatments are employed, 
including surgery or radiotherapy. In advanced disease, the 
treatment typically involves multimodality options, including 
surgery followed by radiotherapy, surgery, and chemoradio-
therapy (CRT). Radical treatment can often be necessary to 
serve the main objective of survival in traditionally aggressive 
disease. In this type of disease, recurrence is not uncommon 
and often occurs within 18 months. In those who develop 
recurrent disease, median overall survival with current CRT 
regimens is 6–8 months.10,11
Surgical ablative options include neck dissection for 
cervical metastasis and open, laser-, or robotic-assisted 
tumor extirpation. Reconstruction using local, regional, or 
free tissue transfer is often employed to restore function 
and address osteoradionecrosis in irradiated patients.12,13 
Conventional external-beam radiotherapy involves 65–70 
Gy over 35 treatments, yet this regimen continues to undergo 
refinement for HPV-related tumors. In addition, advances 
in intensity-modulated radiation therapy have portended 
reduced damage to adjacent structures, further refining the 
area and dose of radiation.14,15 Chemotherapy regimens are 
usually platinum-based, but can include taxanes and 5-fluo-
rouracil in some institutions. Various relatively new agents 
have emerged targeting inhibition of the epidermal growth 
factor receptor, such as cetuximab, or other aspects of the 
innate immune system, such as ipilimumab or nivolumab. 
In recurrent or metastatic HNC, these human monoclonal 
antibody therapies have shown promising results as check-
point inhibitors, activating inhibited T cells to attack cancer 
cells.16 Several of these agents are currently in trials for these 
advanced indications (ClinicalTrials.gov, NCT02252042).17
While often necessary to achieve the best chance of 
survival, the aforementioned treatments herald both short-
term (acute treatment-related toxicity) and long-term (late) 
adverse effects. These effects can have profound detrimental 
consequences on short- and long-term quality of life and 
well-being.18,19
How does this affect patients and 
care-givers?
Diagnosis and treatment of HNC impacts patients in physi-
cal, social, psychological, emotional, and spiritual domains. 
The main areas affected are shown in Table 1. Each area can 
be targeted in an endeavor to improve health-related quality 
of life. For example, physical concerns may include chew-
ing, eating, dry mouth (xerostomia), fatigue, or appearance. 
Psychological concerns may include depression or anxiety. 
Social concerns may include finance and employment.20,21 
Poor function can portend poor HRQOL and distress.22 Previ-
ous studies have suggested that certain patient demographics 
are associated with poorer recovery in the domains previously 
specified. For example, patients scoring above 10 on the Beck 
Depression Inventory failed to regain normal functioning by 
12 months post-diagnosis across four different HNC-specific 
physical domains, including speech, eating, facial esthetics, 
and social disruption.23 Other demographics demonstrated 
to impact HRQOL are marital status,24 employment status,25 
educational level,26 socioeconomic status,27 and degree of 
comorbidity.28 The diverse nature of the individual response 
is signified by the abundance of published articles reporting 
on HRQOL following HNC.29 This complexity is reflected 
in the numerous abstracts identified on “Handle on QOL”, a 
searchable web-based repository of papers that have reported 
QOL in HNC using questionnaires as patient-reported out-
come measures (PROMs).29
Who comprises the multidisciplinary 
team?
In order to address the varied needs of patients and their care-
givers, HNC care is delivered in a multidisciplinary setting. 
Although the composition of the team varies between units 
and institutions, members often include a surgical oncolo-
gist, nursing staff or clinical nurse specialist, social worker, 
speech and language pathologist, physiotherapist, occupa-
tional therapist, psychologist or psychiatrist, dentist, oral 
rehabilitation specialist, audiologist, and chaplain. 
In its most ideal form, treatment of HNC (regardless 
of type) is delivered in tertiary cancer centers. In these 
Table 1 Areas most commonly affected by HNC and its treatment
Carer Coping
Dental status Disfigurement
Emotion Fatigue
Fear of recurrence Financial/work
Information Lymphedema
Nutrition Oral rehabilitation
Pain Personality
Self-esteem Sociodemographic
Speech Swallowing
Shoulder Trismus
Xerostomia Unknown
Abbreviation: HNC, head and neck cancer.
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 institutions, there is a focus on expert, guideline-enforced 
care with defined roles across the multidisciplinary team. 
However, the consequences of HNC can develop and exist 
remote from the time of treatment, and as such, centraliza-
tion of HNC care is necessary both to ensure close links 
between HNC survivors and multidisciplinary team, and 
between the team and locality from which the patient was 
referred. In the locality, the role of a clinical nurse, family 
physician, and dentist are very important to ensure ongoing 
monitoring and care of late effects of treatment, and possible 
referral to a tertiary care center for further management. This 
communication can be challenging, and as such, advances 
in integrating and digitalizing PROMs into routine clinical 
care and electronic patient records may portend improved 
multidisciplinary correspondence.30
What PROMs are commonly used?
Over the past 3 decades or more, PROMs have been estab-
lished as tools to illustrate patient concerns and perspective. 
PROMs are a key component of evaluating treatment-related 
effects in both cohort studies and clinical trials. They play 
a role in alluding to HRQOL outcomes and identifying dif-
ferences in patient experience between treatment protocols. 
PROMs can be used as screening tools to identify specific 
problem issues and facilitate targeted interventions.31
PROMs are commonly utilized in a self-report question-
naire format, which is predominantly quantitative, to facilitate 
a defined threshold for intervention. However, qualitative 
approaches, including open and semi-structured interviews, 
have also become useful, particularly with respect to the 
psychological domain of HRQOL. Qualitative methodol-
ogy also provides depth to our understanding and can assist 
in the interpretation of correlations found in questionnaire 
data. In addition, this information can be used to improve the 
information patients receive and enhance patient information 
leaflets and consent.32,33 Personal reflections presented from 
the patient perspective can have a profound impact on our 
appreciation of the holistic impact of HNC. 
Given the complex anatomy of the head and neck, a vast 
array of PROMs exist to elucidate HNC symptomatology.34 
“Handle on QOL” gives reference to over 250 different 
questionnaires. The PROMs can be considered in six main 
categories: 1) those addressing cornucopia of issues not 
specific to cancer; 2) those addressing issues common to all 
cancers; 3) questionnaires with items specific to HNC; 4) 
questionnaires that focus on a particular aspect of head and 
neck function; 5) those measuring psychological concerns, 
such as depression, anxiety, or self-esteem; and 6) item 
prompt lists, such as the Patient Concerns Inventory (PCI). 
Given the wide range of issues possibly affected by HNC 
(Table 2), it is clear that no one questionnaire has the ability 
to cover all aspects. Each PRO has its own unique features and 
merits, and there is no gold standard. The situation is further 
complicated as there is no consensus on the standard definition 
for “quality of life” or HRQOL. The measurement of HRQOL 
varies between institutions,35,36 and this makes assessment of 
large datasets difficult. However, the “quality of life” agenda 
has been refined with the focus on HRQOL, with most assess-
ments concentrating on the physical, psychological, and 
social aspects of HNC and their impacts.23 “Handle on QOL” 
Table 2 Domains housing symptoms experienced during 
diagnosis and treatment by HNC patients as based on the Patient 
Concerns Inventory item prompt list
Physical and functional 
well-being
Treatment-related
Activity Cancer treatment
Appetite Regret about treatment
Bowel habit PEG tube
Breathing Wound healing
Chewing/eating
Coughing Social care and social well-being
Dental health/teeth Carer
Dry mouth Dependents/children
Energy levels Financial benefits
Fatigue/tiredness Home care/district nurse
Hearing Lifestyle issues (smoking/alcohol)
Indigestion Recreation
Mobility Relationships
Mouth opening Speech/voice/being understood
Mucous Support for my family
Nausea
Pain in the head and neck Psychological, emotional and 
spiritual well-being
Pain elsewhere Appearance
Regurgitation Angry
Salivation Anxiety
Shoulder Coping
Sleeping Depression
Smell Fear of the cancer coming back
Sore mouth Fear of adverse events
Swallowing Intimacy
Swelling Memory
Taste Mood
Vomiting/sickness Self-esteem
Weight Sexuality
Spiritual/religious aspects
Personality and temperament
Abbreviations: HNC, head and neck cancer; PEG, percutaneous endoscopic 
gastrostomy tube.
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provides access to over 150 papers on questionnaire develop-
ment and validation.29 While most PROMs can be categorized 
as stated previously, it can often be more clinically intuitive 
to professionals and patients to classify them according to 
the key stages encountered by the patient. While the length 
and adversity of each stage may vary between patients, the 
patients present with similar concerns at each stage that can 
be quantified and monitored. Questionnaires relevant to the 
described key stages are demonstrated in Table 3. 
As treatments for HNC change over time, existing ques-
tionnaires require adjustment to ensure accurate assessment. 
An example of this is the European Organization for Research 
and Treatment of Cancer (EORTC) QOL Module for HNC 
(QLQ-H&N43).37 This was felt advisable given the deficits 
in the original EORTC HNC module in relation to targeted 
and/or multimodal therapy.38
What are the key periods in the 
patient journey?
HNC patients can experience symptoms in clinically distinct 
key stages, outlined as diagnosis, treatment, acute toxicity, 
early recovery, late effects, recurrence, and palliation.
Diagnosis
Disclosing a diagnosis of HNC to a patient requires an indi-
vidually-tailored approach. Information provided to patients 
should be clear, concise, and specific to the  individual, as 
each patient desires a different level of detail in explana-
tion.39 Additionally, PROMs may assist with decision-making 
regarding chosen treatment path following diagnosis. Ques-
tionnaires exist to allow clinicians to assess satisfaction with 
information provision among HNC patients. An example 
of this is the Satisfaction with Cancer Information profile, 
a validated measure of satisfaction with information about 
treatment, which is responsive to change.40
The Patient Concerns Inventory (Diagnosis) (PCI-D) is an 
item prompt list intended to prompt patients to inquire about 
aspects of their cancer diagnosis, potential treatments, and 
outcomes.41 Aside from assessing patient symptomatology, it 
additionally provides a prompt list to prioritize items of dis-
cussion with different members of the multidisciplinary team.
The feasibility of answering the question, “What will 
I be like after my treatment of HNC?” has been improved 
with expanded, longitudinal PRO datasets.42,43 These datasets 
can yield further detailed subgroup analysis of HRQOL, 
which may in turn provide patients and practitioners with a 
more accurate extrapolation of long-term PROs. However, 
the benefit of managing patient expectations by forecasting 
HRQOL outcomes after treatment needs further evaluation.
Treatment
As mentioned, qualitative methods have been used to inform 
patients and practitioners as to the patient perspective during 
treatment. Examples of this may include patients’ experience 
Table 3 Examples of patient-reported outcomes relating to HRQOL during key stages of HNC
Diagnosis •	 Patient Concerns Inventory-Diagnosis41
•	 Satisfaction with Cancer Information profile (SCIP)40
Treatment •	 Hospital Anxiety Depression Scale (HADS)83
•	 Symptom Severity Scale (SSS)84
•	 Visual Analog Scale (VAS)85
Acute toxicity •	 Late Effects in Normal Tissue (LENT)86/Subjective-Objective-Management-Analytic (SOMA)49
•	 Common Terminology Criteria for Adverse Events (CTC-AE)87
•	 Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN)88
Early recovery •	 EuroQOL EQ-5D-5L89 
•	 European Organization for Research and Treatment of Cancer (EORTC) QLC-C3090 and EORTC H&N 3591
•	 Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N)92
•	 University of Washington Quality of Life Scale (UW-QoL v4)93
•	 Patient Concerns Inventory (PCI-HN)58
Late effects •	 Oral rehabilitation: Liverpool Oral Rehabilitation Questionnaire (LORQ)94
•	 Trismus: Gothenburg Trismus Questionnaire (GTQ)95
•	 Swallowing: Swallowing Quality of Life Questionnaire (SWAL-QOL)96
•	 Xerostomia Questionnaire (XQ)97
Recurrence •	 Vanderbilt Head and Neck Symptom Survey (VHNSS)98
Palliation •	 EORTC QLQ-C15-PAL99
•	 Family Assessment of Treatment at the End of life (FATE)100
•	 Schedule for the Evaluation of Individual Quality of Life (SEIQoL)76
Abbreviation: HRQOL, health related quality of life; HNC, head and neck cancer.
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of temporary tracheostomies after microvascular reconstruc-
tion for cancer of the head and neck,33 and patients’ experi-
ences in the early recovery phase following carbon dioxide 
laser removal of oral SCC.32 These approaches help to high-
light predominant patient concerns to the treatment team and 
enhance preoperative teaching and patient resource materials. 
PROMs are also used to help inform patients about dif-
ferences in short- and long-term morbidity between different 
treatment options. This becomes pertinent when no discussion 
regarding the trade-off between cure and HRQOL is planned. 
In this situation, the compromise is weighted toward treatment 
that offers the best chance of cure. However, PROMs can be 
very useful when discussing a specific aspect of the treatment, 
such as the comparison of patient- and surgeon-rated morbid-
ity following deep circumflex iliac artery and fibula free tis-
sue transfer.44 This point can be additionally demonstrated in 
circumstances when survival between two treatments is very 
similar. For example, in early laryngeal cancer, PROMs may 
reflect differences in HRQOL priorities and aid in decision-
making between primary radiotherapy and laser ablation.45
PRO assessment during treatment adds an additional 
patient burden at a challenging time. Hence, to date, there are 
relatively few studies in this area. Some institutions are now 
employing the use of tablet devices and web applications to 
provide a more comfortable environment for repeated PRO 
reporting by the patient.46,47,48 This concept will be discussed 
in more detail later in ‘The way forward’ section.
Acute toxicity
Historically, acute toxicity has not been the focus of HRQOL 
assessment, given its relatively brief duration in the patient 
journey. However, PROMs in this key stage of HNC care can 
impact further coping and rehabilitation. In 1995, the EORTC 
and Radiation Therapy Oncology Group developed the Late 
Effects Normal Tissue Task Force - Subjective, Objective, 
Management, Analytic (LENT-SOMA) scale (31-item scale 
assessing mucosal integrity, management of ulceration, skin 
(edema, alopecia, pigmentation, necrosis, and fibrosis), sali-
vary glands, trismus, and dentition.49 In 2010, the National 
Cancer Institute published the Common Terminology Criteria 
for Adverse Events, which incorporated the LENT-SOMA 
items with early and late effects of head and neck radio-
therapy.50 A relationship was observed between toxicity as 
measured by the LENT-SOMA scale and HRQOL as mea-
sured by EORTC QLQ-C30 and QLQ-H&N35.51 Similar 
findings have been reported when using the observer-based 
toxicity scoring system published by the Danish Head and 
Neck Cancer study group.19 While PROMs were not included 
in these assessment tools, the aforementioned study findings 
would support a need for their inclusion in future versions.19
Previous studies have demonstrated that real-time collec-
tion of PRO data can be used to monitor adverse events during 
radiotherapy or concurrent CRT treatments. When completed 
consistently throughout treatment, congruent early interven-
tion can be employed to mitigate the toxicity of treatment.49
Early recovery
PROMs completed soon after the completion of treatment 
can help to screen patients for dysfunctional symptoms that 
may delay or inhibit rehabilitation, temporarily or perma-
nently. The degree of dysfunction can vary between patients 
and may not necessarily equate to the objective assessment. 
For example, some patients may report minimal dysphagia 
symptoms, yet display silent aspiration on imaging studies. 
Other patients may report significant cosmetic concerns, 
which may not be readily evident during casual interaction. 
Yet, combining objective outcome measures with PRO may 
allow for targeted interventions in the early stages of prospec-
tive studies or clinical trials. The majority of PROM papers 
address the “early recovery” phase following HNC. While 
there is no precise definition of “early”, it would be reasonable 
to consider this as from 3 months post-treatment completion 
to up to 5 years. There are several review articles which sum-
marize the choice and selection of PRO available.35,36,52–55 
Common issues during this key stage are fear of recur-
rence, dental health/teeth, taste, salivation, chewing, swallow-
ing, mouth opening, fatigue, sleeping, speech, and pain.56,57 
Not unexpectedly, given the complexity of the head and neck 
region, a multitude of these concerns arise during the clinic 
interview. The PCI-HN is an HNC-specific prompt list to help 
enable patients to raise concerns in a prioritized manner.58 The 
PCI has 57 items and can be used alongside standard HNC 
cancer-specific HRQOL questionnaires.59 This combination 
of PROMs is useful as it allows a measure of dysfunction as 
well as an indication of the degree to which it concerns the 
patient. Therein, by reflecting on patient-prioritized issues 
within the PCI or other PROMs, it is possible to refine treat-
ments to target PROMs dysfunction without diminishing cure 
rates. For example, priorities in patients treated by primary 
surgery for oral and oropharyngeal cancer are chewing and 
swallowing.60 
PROMs can give an indication of cost utility, quality-
adjusted life years, and a suggestion of health care costs 
when combined with direct and indirect cost assessments. 
A questionnaire of established repute in this context has 
been developed by the EuroQol Group (EQ5D-5L), and 
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this PRO is a generic questionnaire suitable for other health 
states and HNC.61
Late effects
Late effects often present as delayed dysfunction as a result 
of previous cancer treatment. These effects often include 
xerostomia, dental decay, dysphagia, pathologic fractures, 
soft tissue fibrosis, and osteoradionecrosis, and often arise 
many months or years post-treatment.62,63
Mandibular osteoradionecrosis results from compromised 
blood supply to the mandible as a result of radiotherapy. 
Osteoradionecrosis can be painful and cause difficulties 
maintaining a normal diet and weight, imparting significant 
detrimental effects on HRQOL.64 Free tissue transfer with 
an osteocutaneous free flap can replace the necrotic bone 
and allow for chewing rehabilitation; however, only a mod-
est improvement in HRQOL is observed postoperatively.65 
While a reduction in pain is offered by free tissue transfer, 
other persistent late effects from radiotherapy such as trismus, 
xerostomia, and speech and swallowing difficulties hinder 
further improvements in HRQOL. 
The reduction in saliva, the direct damage to teeth 
structure by radiotherapy, and the reduced turnover of tis-
sue related to the periodontal membrane leads to radiation-
induced carries, periodontal disease, and earlier than expected 
dental extractions. The combination of reduction in salivary 
flow, compromised blood supply to periodontal structures, 
and reduced cell turnover in the periodontal membrane can 
cause significant dental decay in the late effect stage, often 
requiring complete dental extractions. Given the noted prior-
ity of odontogenic concerns in most PROMs, ongoing sup-
port and monitoring of the remaining dentation is essential. 
For a select group of patients, placement of osseointegrated 
implants can positively impact HRQOL outcomes.66 As there 
is often a need to justify placement of a resource-intensive 
intervention such as osseointegrated implants, assessment 
of the potential improvement in HRQOL has previously 
been demonstrated on the Liverpool Oral Rehabilitation 
Questionnaire.67
Dysphagia and chewing difficulties remain a persistent 
hindrance in the late effects stage. This is thought to be due 
to progressive fibrosis of the pharyngeal constrictor muscles, 
larynx, and the proximal esophageal sphincter.68 Severe 
dysphagia may develop or progress years after head and 
neck radiotherapy and lead to gastrostomy dependence.63 
Permanent gastrostomy tubes have previously been associated 
with the poorest PROMs through interference with family 
life, intimate relationships, social activities, and hobbies.69
Late effects of radiotherapy or chemotherapy are not 
easy to predict and can be dose-dependent or pharmaco-
logically specific. Progressive cognitive dysfunction can be 
a ubiquitously reported PRO, particularly in elderly cancer 
patients. However, patients undergoing CRT for cancer of 
the nasopharynx are particularly at risk of this outcome.70
Recurrence
Recurrent and/or unresectable HNC is a challenging scenario. 
Treatment is of limited benefit, and often associated with 
significant toxicity. Thus, projected HRQOL as reported on 
PROMs should be prioritized in the choice of treatment.71 
HRQOL of patients receiving platinum-based chemotherapy 
plus cetuximab first line for recurrent and/or metastatic 
HNC has been shown to be acceptable.72 However, of inter-
est is the effect of administration of immune checkpoint 
inhibitors on HRQOL, such as nivolumab, in patients with 
platinum-refractory, recurrent HNC. A previous study has 
demonstrated better PROMs and longer overall survival 
with administration of nivolumab when compared to that of 
conventional agents.16 
Palliation
While the preceding key stages in the HNC journey can be 
prolonged, time spent in the palliative stage is often limited to 
several months. During this time, treatments are provided in 
short intervals and attempts are made to considerably reduce 
treatment toxicity.73
A scope for PROM-dictated palliative treatments for 
HNC exists, pertaining to death outside of the hospital and 
palliative care team involvement.74 For example, the use of 
the Family Assessment of Treatment at the End of life may 
improve both care-giver and patient support during this 
stage.75 The importance of care-giver support in HNC can-
not be underestimated.75 As both physical and psychological 
concerns can change rapidly during this phase, PROMs 
using patient-generated indices have merit. An example of 
this exists in the Schedule for the Evaluation of Individual 
Quality of Life.76 These are more time consuming to complete 
and uniquely derived by individuals, hence are not frequently 
reported in the HNC literature.
Potential benefits of using PROMS 
to guide patients and professionals 
Using PROMs to inform and guide both patients and profes-
sionals in clinical practice can confer a myriad of benefits. 
The main benefits, as discussed in the previous sections, 
are in providing patient information, predicting HRQOL, 
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enhancing screening, targeting interventions, and improving 
communication between the patient and multidisciplinary 
team within the cancer center and the locality.
More recently, authors have directed attention toward 
creating PROMs that are more clinically applicable and 
focused on well-defined patient groups and treatments. This 
data will allow for more informed shared decision-making 
strategies amongst the multidisciplinary team.77
Barriers to using PROMS to guide 
patients and professionals about the 
patients 
Predominant reasons cited by head and neck consultants for 
not using HRQOL questionnaires included lack of resources 
and unproven value.78 Authors have previously identified a 
misconception amongst clinicians affirming that PROMs 
are a research tool only rather than an adjunct to providing 
patient care and education.79 In addition, including these 
assessments can introduce both a time and paper burden to 
clinical practice. However, as discussed in the next section, 
the use of information technology can reduce burden and may, 
in fact, improve clinical efficiency while providing patient 
care and education. As such, future studies must capitalize 
on building an evidence base for the contribution of PROMs 
to the care of the HNC patient. 
The way forward
The digital revolution
The utility of PROMs moving forward will be enhanced by 
the inevitable digital revolution of the health care sector. 
PROMs provided by web applications on smartphones and 
tablets will allow remote and out-of-hospital reporting. By 
the same token, alerting the treatment team to significant 
or severe concerns will be facilitated through the use of 
web applications. Contemporaneous collection of data by 
practitioners will allow for efficient review and targeted 
interventions across a range of physical, emotional, social, 
spiritual, and family domains. The efficiency provided by 
PROMs in the care of HNC patients may have implications 
for reduction in overall morbidity and subsequent health 
care costs. PROMs will allow for earlier identification of 
struggling patient, and provide an opportunity for targeted 
intervention prior to physical or psychological deterioration. 
The integration of PROMs into routine care may also reduce 
overall health care costs. There are several examples of how 
PROMs are being framed within the context of digitized 
care in HNC, such as the dashboard of “Kaiku”,48 electronic 
PRO and toxicities,49 electronic QOL assessment using tablet 
devices during and after treatment,47 the eHealth application 
“OncoKompas”,80 and the PCI.81
The enhanced clinical interaction
The combination of using established HRQOL question-
naires and an item prompt list like the PCI opens up the 
opportunity for enhanced consultations.59 This approach 
recognizes the limitations inherent in HNC HRQOL 
questionnaires with respect to a large scope of issues, but 
acknowledges the value of validated tools to indicate those 
patients with worse outcomes. It also realizes the value of 
allowing patients to identify a list of prioritized issues to 
discuss during the clinical interaction. These two approaches 
are efficient enough to be integrated into routine clinical 
care, with all the advantages this confers.82 Patients find the 
completion of such tools relatively uncomplicated, and by 
using a digital platform it is possible to build in Computer-
Adaptive Tests which allow for the answer to one item of 
a questionnaire to lead to another specified question. Thus, 
the questionnaire battery can be individualized to the patient 
through adaptation of the questions asked, thereby optimiz-
ing measurement precision and minimizing questionnaire 
burden.82
Conclusion
PROMs present an opportunity for enhanced discussion 
between the clinician and patient throughout the HNC 
journey. The value of PROMs has evolved beyond the 
research context, and now lies in providing patient informa-
tion, predicting HRQOL, enhancing screening, targeting 
interventions, and improving communication between the 
patient and multidisciplinary team. The enhanced clinical 
interaction delivered by the use of PROMs in diagnosis and 
treatment can allow for tailored rehabilitation and further 
refinement of future, rapidly evolving treatment regimens. 
Digitalization of PROMs may provide congruently prompt 
real-time patient feedback to better deliver patient care. This 
review was conducted in accordance with the principles of 
the Declaration of Helsinki.
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